{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:21:55Z","timestamp":1793305315621,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020582","name":"National Institute of Pharmaceutical Education and Research, Raebareli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jpba.2024.116533","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T05:56:54Z","timestamp":1729144614000},"page":"116533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Characterization of disulfide bridges containing cyclic peptide Linaclotide and its degradation products by using LC-HRMS\/MS"],"prefix":"10.1016","volume":"252","author":[{"given":"Sachin","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Titkare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpba.2024.116533_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2050640612474446","article-title":"Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation","volume":"vol. 1","author":"Corsetti","year":"2013","journal-title":"U. Eur. Gastroenterol. J."},{"issue":"1","key":"10.1016\/j.jpba.2024.116533_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/jpet.112.199430","article-title":"Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation","volume":"vol. 344","author":"Busby","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2024.116533_bib3","doi-asserted-by":"crossref","unstructured":"S. Mozaffari, S. Nikfar, and M. Abdollahi, Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome, Apr. 2013. doi: 10.1517\/17425255.2013.759558.","DOI":"10.1517\/17425255.2013.759558"},{"issue":"11","key":"10.1016\/j.jpba.2024.116533_bib4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14656566.2018.1494728","article-title":"Linaclotide for the treatment of chronic constipation","volume":"vol. 19","author":"Bassotti","year":"2018","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.jpba.2024.116533_bib5","series-title":"Recent advancements in disulfide bridge characterization: Insights from mass spectrometry","author":"Chaturvedi","year":"2024"},{"issue":"13","key":"10.1016\/j.jpba.2024.116533_bib6","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1002\/jssc.202101034","article-title":"Synthetic pharmaceutical peptides characterization by chromatography principles and method development","volume":"45","author":"Sharma","year":"2022","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2024.116533_bib7","doi-asserted-by":"crossref","unstructured":"S.H. Joo, Cyclic peptides as therapeutic agents and biochemical tools, Jan. 2012. doi: 10.4062\/biomolther.2012.20.1.019.","DOI":"10.4062\/biomolther.2012.20.1.019"},{"issue":"2","key":"10.1016\/j.jpba.2024.116533_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1556\/1326.2017.29.2.05","article-title":"Stress testing of linaclotide: Development of a validated stability-indicating RP-HPLC method","volume":"vol. 29","author":"Pyla","year":"2017","journal-title":"Acta Chromatogr."},{"issue":"03","key":"10.1016\/j.jpba.2024.116533_bib9","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9872.1000366","article-title":"Analysis and preparation of linaclotide by high performance liquid chromatography","volume":"vol. 08","author":"Zhu","year":"2017","journal-title":"J. Anal. Bioanal. Tech."},{"key":"10.1016\/j.jpba.2024.116533_bib10","unstructured":"S. Biotech, Techniques used for development of Stability Indicating Methods (SIM) include HPLC\/UHPLC, while those for characterization of the degradation products include hyphenated mass, IR and NMR systems, of which most popular are LC-MS (HRMS and MS n) and LC NMR instruments Identification and Control of Pseudo Degradation Products during Stress Testing on Drugs, 2019."},{"key":"10.1016\/j.jpba.2024.116533_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2016.05.008","article-title":"Forced degradation study of racecadotril: Effect of co-solvent, characterization of degradation products by UHPLC-Q-TOF-MS\/MS NMR and cytotoxicity assay","volume":"vol. 128","author":"Chiguru","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116533_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jpba.2015.07.028","article-title":"Forced degradation of fingolimod: Effect of co-solvent and characterization of degradation products by UHPLC-Q-TOF-MS\/MS and 1H NMR","volume":"vol. 115","author":"Patel","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"18","key":"10.1016\/j.jpba.2024.116533_bib13","doi-asserted-by":"crossref","first-page":"8178","DOI":"10.1039\/D0NJ05781A","article-title":"Stress degradation study of bortezomib: Effect of co-solvent, isolation and characterization of degradation products by UHPLC-Q-TOF-MS\/MS and NMR and evaluation of the toxicity of the degradation products","volume":"vol. 45","author":"Udutha","year":"2021","journal-title":"New J. Chem."},{"issue":"5","key":"10.1016\/j.jpba.2024.116533_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.9696","article-title":"LC\/Q-TOF-MS-based structural characterization of enasidenib degradation products and establishment of a stability-indicating assay method: Insights into chemical stability","volume":"38","author":"Chakkar","year":"2024","journal-title":"Rapid Commun. Mass Spectrom."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524005752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524005752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T19:28:03Z","timestamp":1730662083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524005752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":14,"alternative-id":["S0731708524005752"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116533","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of disulfide bridges containing cyclic peptide Linaclotide and its degradation products by using LC-HRMS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116533"}}